drugset / Trial / NCT06364046
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This project aims to conduct a prospective, single-center, randomized, open-label, two-arm study to compare the clinical efficacy and safety of bronchial arterial chemoembolization with drug-eluting beads (DEB-BACE) combined with serplulimab versus conventional intravenous chemotherapy combined with Serplulimab as first-line treatment for SCLC patients. The objective is to provide evidence-based support for clinical practice.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serplulimab | Monoclonal antibody | 200 mg | Intravenous |